Trial Profile

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary) ; Pembrolizumab (Primary) ; LHRH receptor agonists; LHRH receptor antagonists
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Sponsors Merck Sharp & Dohme

18 Mar 2025 Planned End Date changed from 15 Jun 2026 to 30 Sep 2025.
20 May 2024 Planned End Date changed from 2 Feb 2026 to 15 Jun 2026.
18 Apr 2024 New source identified and integrated (European Clinical Trials Database: EudraCT2019-003633-41 ).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com